Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
Read More…
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Phone520-365-3100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.67 million
Profitability
Miscellaneous
Employees287
Next Earnings Date11/7/2019 (Confirmed)
OptionableOptionable
Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions
What is Accelerate Diagnostics' stock symbol?
Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."
How were Accelerate Diagnostics' earnings last quarter?
Accelerate Diagnostics Inc (NASDAQ:AXDX) released its quarterly earnings data on Thursday, August, 8th. The medical research company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. The medical research company had revenue of $1.81 million for the quarter, compared to analysts' expectations of $2.71 million. Accelerate Diagnostics had a negative return on equity of 170.47% and a negative net margin of 1,293.91%. View Accelerate Diagnostics' Earnings History.
When is Accelerate Diagnostics' next earnings date?
How can I listen to Accelerate Diagnostics' earnings call?
Accelerate Diagnostics will be holding an earnings conference call on Thursday, November 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for AXDX?
3 equities research analysts have issued twelve-month target prices for Accelerate Diagnostics' stock. Their predictions range from $16.00 to $19.00. On average, they expect Accelerate Diagnostics' stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 4.1% from the stock's current price. View Analyst Price Targets for Accelerate Diagnostics.
What is the consensus analysts' recommendation for Accelerate Diagnostics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accelerate Diagnostics.
What are Wall Street analysts saying about Accelerate Diagnostics stock?
Here are some recent quotes from research analysts about Accelerate Diagnostics stock:
- 1. According to Zacks Investment Research, "Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado. " (7/10/2019)
- 2. BTIG Research analysts commented, "Neutral AXDX reported Q1 revenue of $1.75M, short of consensus’ $1.9M forecast. Revenue was down sequentially by 4%. Although we had expected a revenue stepdown given the typical cadence of placements-to- conversions, the magnitude of the decline was less than we expected. In Q1, the company added 75 commercially contracted placements vs. 133 in 4Q18; to clarify, commercial placements refer to customers that have agreed to install and run tests (may or may not be active users). The company still sees a 4-9 month lag before instruments become active. On expectations for 2019, mgmt continues to target 300-400 placements as a full transition to the rental model and more comprehensive body of positive studies may drive up volumes." (5/12/2019)
Has Accelerate Diagnostics been receiving favorable news coverage?
Media stories about AXDX stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Accelerate Diagnostics earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Accelerate Diagnostics.
Who are some of Accelerate Diagnostics' key competitors?
Some companies that are related to Accelerate Diagnostics include Horiba (HRIBF), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), Arrayit (ARYC), BioNano Genomics (BNGO), Precipio (PRPO), Scientific Industries (SCND), Aethlon Medical (AEMD), Pressure Biosciences (PBIO) and PositiveID (PSID).
What other stocks do shareholders of Accelerate Diagnostics own?
Who are Accelerate Diagnostics' key executives?
Accelerate Diagnostics' management team includes the folowing people:
- Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 53)
- Mr. Steve Reichling, Chief Financial Officer (Age 41)
- Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 55)
- Mr. Kurt Reinhardt, Head of Operations
- Dr. Romney M. Humphries, Chief Scientific Officer (Age 38)
Who are Accelerate Diagnostics' major shareholders?
Accelerate Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include TCI Wealth Advisors Inc. (0.10%), CIBC Private Wealth Group LLC (0.09%) and SeaCrest Wealth Management LLC (0.06%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View Institutional Ownership Trends for Accelerate Diagnostics.
Which institutional investors are selling Accelerate Diagnostics stock?
Which institutional investors are buying Accelerate Diagnostics stock?
AXDX stock was acquired by a variety of institutional investors in the last quarter, including TCI Wealth Advisors Inc. and SeaCrest Wealth Management LLC. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View Insider Buying and Selling for Accelerate Diagnostics.
How do I buy shares of Accelerate Diagnostics?
Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Accelerate Diagnostics' stock price today?
One share of AXDX stock can currently be purchased for approximately $16.81.
How big of a company is Accelerate Diagnostics?
Accelerate Diagnostics has a market capitalization of $916.41 million and generates $5.67 million in revenue each year. The medical research company earns $-88,330,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.View Additional Information About Accelerate Diagnostics.
What is Accelerate Diagnostics' official website?
How can I contact Accelerate Diagnostics?
Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]
MarketBeat Community Rating for Accelerate Diagnostics (NASDAQ AXDX)
MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe AXDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
